We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tumor Markers Associated with H. Pylori Infection

By LabMedica International staff writers
Posted on 19 Sep 2018
Print article
Image: Immunostaining of Helicobacter pylori infection in the small intestine. The small spiral-curved shaped bacterium can be seen clearly using a ×100 oil objective under the microscope (Photo courtesy of BioCare Medical).
Image: Immunostaining of Helicobacter pylori infection in the small intestine. The small spiral-curved shaped bacterium can be seen clearly using a ×100 oil objective under the microscope (Photo courtesy of BioCare Medical).
Helicobacter pylori infection is a major cause of several cancers such as gastric, pancreatic and lung. The relationship between H. pylori and tumor markers continues to remain unclear. As one of the leading causes of morbidity and mortality globally, cancer represents a major detrimental public health problem worldwide.

There are various known important tumor biomarkers in cancer progression such as carcinoembryonic antigen (CEA), cancer antigens (CA) 153, CA199, CA724, CA125 and alpha-fetoprotein (AFP) which have been shown in the past to have various evidence in diagnostic modalities. These tumor markers were reported to have a close relationship with specific cancers.

A team of scientists led by those at Aerospace Center Hospital (Beijing, China) carried out a observational retrospective study and recruited a total of 14,689 subjects were included and 6,493 (44.2%) subjects were infected by H. pylori. The subjects had a mean age of 45 ±18 years. There were 4,530 (31.0%) female subjects. H. pylori infection status was assessed by ELISA specific for anti-H. pylori antibodies, particularly IgG and IgM. If both serological testing results were positive, the subject was diagnosed as H. pylori infection.

Cut-off values were administered to distinguish whether tumor marker levels were normal or abnormal. According to previous studies, the cut-off values of serum CEA, AFP, CA199, CA724, CA153 and CA125 were set to 5 ng/mL, 10 ng/mL, 37 U/mL, 10 U/mL, 25 U/mL and 35 U/mL, respectively. The ratios of individual biomarkers were measured between the two groups. The ratio is defined according to the cut-off value. Abnormal ratio means the percentage of individuals with abnormal CEA (i.e., CEA>5 ng/mL) in total H. pylori (+) subjects or individuals with abnormal CEA in total H. pylori (−) subjects.

The scientists reported that after adjusting for the confounding factors, infections with H. pylori were found to be significantly associated with abnormal ratios in CEA, AFP and CA724 of H. pylori (+) to H. pylori (–) groups. Significant positive correlation was found between H. pylori infection and CEA values. Significant differences were found in both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels between H. pylori (+) and H. pylori (−) groups.

The authors concluded that in their observational retrospective study illustrated that higher abnormal ratios of CEA, AFP and CA724 were observed in infected to uninfected subjects. Higher level of CEA was also found to be related to H. pylori infection after controlling confounders. The serological testing for the presence of two antibodies against H. pylori, IgG and IgM, indicate a past exposure to this bacterium rather than a current exposure. These findings could aid in the earlier diagnosis and intervention provided to better patient’s quality of life. The study was published on August 23, 2018, in the journal BMJ Open.

Related Links:
Aerospace Center Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.